Get the Stockscreener App
13.95
3.72%
0.50
After Hours:
13.60
-0.35
-2.51%
Avalo Therapeutics Inc stock is traded at $13.95, with a volume of 1.14M.
It is up +3.72% in the last 24 hours and down -17.24% over the past month.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
See More
Previous Close:
$13.45
Open:
$14.26
24h Volume:
1.14M
Relative Volume:
2.30
Market Cap:
$258.25M
Revenue:
$59,000
Net Income/Loss:
$-78.26M
P/E Ratio:
-2.2882
EPS:
-6.0964
Net Cash Flow:
$-51.46M
1W Performance:
-4.97%
1M Performance:
-17.24%
6M Performance:
+20.78%
1Y Performance:
+63.35%
1-Day Range:
$13.49
$14.79
1-Week Range:
$13.07
$15.25
52-Week Range:
$3.39
$20.72
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
13.95 | 249.00M | 59,000 | -78.26M | -51.46M | -6.0964 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-25 | Initiated | TD Cowen | Buy |
| Aug-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Analysis Recap: Is Avalo Therapeutics Inc in a bullish channel2026 Setups & Momentum Based Trading Ideas - baoquankhu1.vn
Avalo Therapeutics (NASDAQ:AVTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Avalo Therapeutics price target to $40 on trial confidence - Investing.com
AVTX: HC Wainwright Raises Price Target, Maintains Buy Rating | - GuruFocus
H.C. Wainwright Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Avalo Therapeutics 2025 Financial Review - AlphaStreet
Is Avalo Therapeutics Inc a potential multi bagger2026 Investor Takeaways & AI Forecast Swing Trade Picks - baoquankhu1.vn
AVTX: BTIG Reiterates Buy Rating with $40 Price Target | AVTX St - GuruFocus
Avalo Therapeutics (NASDAQ:AVTX) Earns Buy Rating from BTIG Research - MarketBeat
Mizuho Securities Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $39 - Moomoo
AVTX: BTIG Reiterates Buy Rating with $40 Price Target | AVTX Stock News - GuruFocus
BTIG Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Avalo Therapeutics stock maintains Buy rating at BTIG ahead of trial - Investing.com
Key facts: Avalo Therapeutics posts $78.3M 2025 loss; Q4 EPS -$1.13 - TradingView
Guggenheim reiterates Buy rating on Avalo Therapeutics stock By Investing.com - Investing.com Canada
Guggenheim reiterates Buy rating on Avalo Therapeutics stock - Investing.com
Avalo Therapeutics Reports 2025 Financial Results and Prepares for Key Phase 2 LOTUS Trial Data of AVTX-009 in Hidradenitis Suppurativa - Minichart
Avalo Therapeutics 2025 Annual Report: Clinical Pipeline, Regulatory Risks, and Competitive Landscape - Minichart
Avalo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Avalo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Avalo Therapeutics (NASDAQ:AVTX) Releases Quarterly Earnings Results, Beats Expectations By $1.17 EPS - MarketBeat
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates - The Manila Times
AVTX: 2025 saw higher R&D spending and net loss, with cash runway projected into 2028 - TradingView
Avalo 10-K: $0.0M Revenue, $78.3M Net Loss — Outlook Through 2028 - TradingView
Avalo Therapeutics (NASDAQ: AVTX) outlines HS trial plans and cash runway - Stock Titan
Avalo Therapeutics (Nasdaq: AVTX) details 2025 loss and LOTUS trial plans - Stock Titan
Avalo nears Q2 results in 250-patient skin disease drug trial - Stock Titan
Earnings Scheduled For March 23, 2026 - Sahm
If You Invested $1,000 in Avalo Therapeutics Inc (AVTX) - Stock Titan
Aug Sectors: Is Avalo Therapeutics Inc a potential multi baggerEarnings Recap Report & Real-Time Market Trend Scan - baoquankhu1.vn
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
AVTX Q4'25 Earnings: revenue estimate is 0 USD - TradingView
Cantor Fitzgerald L. P. Makes New $1.08 Million Investment in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Top Executive Makes Major Move With Avalo Therapeutics Stock - TipRanks
Avalo Therapeutics chief medical officer sells $411k in stock By Investing.com - Investing.com South Africa
Avalo Therapeutics (NASDAQ:AVTX) Insider Sells $411,695.80 in Stock - MarketBeat
Avalo Therapeutics chief medical officer sells $411k in stock - Investing.com
Avalo Therapeutics (AVTX) CMO exercises options, sells 25,492 common shares - Stock Titan
Panic Selling: Is Avalo Therapeutics Inc undervalued by DCF analysisOptions Play & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Avalo Therapeutics, Inc. $AVTX Shares Acquired by Boothbay Fund Management LLC - MarketBeat
[144] Avalo Therapeutics, Inc. SEC Filing - Stock Titan
Cantor Fitzgerald L. P. Acquires New Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Boxer Capital Management LLC Invests $1.59 Million in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Ally Bridge Group NY LLC Purchases New Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at Conference - MarketBeat
Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Can Avalo Therapeutics Inc. stock hit analyst price targets2025 Earnings Surprises & Safe Swing Trade Setups - Naître et grandir
Avalo Therapeutics Highlights AVTX-009 Plan, Near-Term Phase II HS Data at Healthcare Conference - Defense World
FMR LLC holds 2.13M shares of Avalo Therapeutics (NASDAQ: AVTX) — 11.5% - Stock Titan
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):